Zenvision Pharma - Due diligence report

A 360° intelligence report on Zenvision Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signa…

2015-06-19 Mumbai, Maharashtra Active
Share
Connect MCP
ZP Zenvision Pharma
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Zenvision Pharma — 360° Intelligence Report

Generated from MCA filings & public records
82/100
Trust Score
Low Risk

Zenvision Pharma is assessed as Low Risk with a Trust Score of 82/100. Zenvision Pharma is an active limited liability partnership incorporated in 2015, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 01 Oct 2026 from the latest processed filings. Msp Medicines Llp snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Profitable - internal accruals available.

Charges position: 2 open (32.98 cr) · 1 satisfied (1.90 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Bank Of India1 48.0 cr
Canara Bank1 48.0 cr
Profectus Capital Private Limited1 48.0 cr
Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
SUNIL HARIPANT POPHALE 01234567 Director 01/04/2018 6 yrs Approved
PARAS VINOD GANDHI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 11+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
2 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment70/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 32.98 cr already registered.
  • Compliance record supports lending.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 10 events
22 Jan 2026
Director ceased
BOBBA VENKATA SIVAKUMAR
31 Mar 2025
Last AGM held
Annual general meeting
03 Sep 2024
Charge satisfied
Profectus Capital Private Limited
31 Mar 2024
Latest balance sheet
Filed with ROC
03 Nov 2022
Charge created
Bank Of India - 31.00 cr
31 May 2022
Charge created
Profectus Capital Private Limited - 1.90 cr
27 Sep 2021
Charge created
Canara Bank - 1.98 cr
01 Sep 2020
Director appointed
PARAS VINOD GANDHI (Partner)
19 Jun 2015
Incorporated
Registered with Roc Mumbai
Director appointed
SUNIL HARIPANT POPHALE (Designated Partner)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
11

Peers & Related Companies

Full peer comparison →
Peer companies will appear here as our matching engine processes this industry.
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Zenvision Pharma before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Zenvision Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Zenvision Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Zenvision Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Zenvision Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Zenvision Pharma an active company?

Zenvision Pharma has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Zenvision Pharma financially healthy?

Zenvision Pharma has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Zenvision Pharma?

Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Zenvision Pharma?

See the directors and ownership sections above for board and shareholding detail. 2 active director(s) are on record.

Does Zenvision Pharma have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Zenvision Pharma up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Zenvision Pharma?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.